Tag Archive for: chemotherapy

The approval came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by itself, reduced the risk of disease progression or death by 58% in specific endometrial cancer patients, compared to chemotherapy alone.

The full results, presented at the annual American Society of Clinical Oncology meeting in Chicago and published in the Journal of Clinical Oncology, show that Trodelvy reduced the risk of death by 16%, with similar improvement for harder-to-treat squamous and non-squamous types of NSCLC.

The drugmaker’s Keytruda therapy in combination with chemotherapy was being evaluated in about 1,095 patients with high-risk endometrial cancer after surgery.

Takeda secured another label expansion for the kinase inhibitor, this time in the first-line setting for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Rybrevant has been approved for use with carboplatin and pemetrexed in the first-line treatment of locally advanced or metastatic non-small cell lung cancer with exon 20 insertion mutations in the EGFR gene.

The drug would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the FDA’s approval was based on trials which extended median progression-free survival (PFS) by nearly nine months.

The agency is investigating reports of secondary blood cancers in patients who have received certain CAR T cell therapies, but experts say the risk is low and is outweighed by the terminal nature of some cancers.

The company announced that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.

The company’s blockbuster cancer drug continues to snap up FDA approvals, this time in treating biliary tract cancer in combination with cisplatin and gemcitabine.

The drug would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the decision from the regulator was based on a late-stage trial which extended median progression-free survival (PFS) by nearly nine months.